Education
About Us
Working with TipRanks
Follow Us
STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Total Valuation
STRATEC Biomedical has a market cap or net worth of €325.78M. The enterprise value is €409.15M.
Market Cap€325.78M
Enterprise Value€409.15M
Share Statistics
STRATEC Biomedical has 12,157,841 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,157,841
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
STRATEC Biomedical’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 5.13%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)5.13%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee176.21K
Profits Per Employee10.96K
Employee Count1,462
Asset Turnover0.58
Inventory Turnover1.54
Valuation Ratios
The current PE Ratio of STRATEC Biomedical is 22.61. STRATEC Biomedical’s PEG ratio is 0.34.
PE Ratio22.61
PS Ratio0.00
PB Ratio1.34
Price to Fair Value1.49
Price to FCF10.67
Price to Operating Cash Flow6.69
PEG Ratio0.34
Income Statement
In the last 12 months, STRATEC Biomedical had revenue of 257.62M and earned 16.02M in profits. Earnings per share was 1.32.
Revenue257.62M
Gross Profit76.39M
Operating Income28.18M
Pretax Income22.01M
Net Income16.02M
EBITDA47.34M
Earnings Per Share (EPS)1.32
Cash Flow
In the last 12 months, operating cash flow was 48.71M and capital expenditures -18.19M, giving a free cash flow of 30.52M billion.
Operating Cash Flow48.71M
Free Cash Flow30.52M
Free Cash Flow per Share2.51
Dividends & Yields
STRATEC Biomedical pays an annual dividend of €0.6, resulting in a dividend yield of 2.05%
Dividend Per Share€0.6
Dividend Yield2.05%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.26
52-Week Price Change-41.55%
50-Day Moving Average25.35
200-Day Moving Average30.63
Relative Strength Index (RSI)57.73
Average Volume (3m)13.42K
Important Dates
STRATEC Biomedical upcoming earnings date is Aug 19, 2025, Before Open (Confirmed).
Last Earnings DateMay 30, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend DateJun 30, 2025
Financial Position
STRATEC Biomedical as a current ratio of 2.47, with Debt / Equity ratio of 53.82%
Current Ratio2.47
Quick Ratio1.17
Debt to Market Cap0.32
Net Debt to EBITDA1.76
Interest Coverage Ratio4.89
Taxes
In the past 12 months, STRATEC Biomedical has paid 5.99M in taxes.
Income Tax5.99M
Effective Tax Rate0.27
Enterprise Valuation
STRATEC Biomedical EV to EBITDA ratio is 9.41, with an EV/FCF ratio of 14.60.
EV to Sales1.73
EV to EBITDA9.41
EV to Free Cash Flow14.60
EV to Operating Cash Flow9.15
Balance Sheet
STRATEC Biomedical has €48.73M in cash and marketable securities with €130.53M in debt, giving a net cash position of €81.81M billion.
Cash & Marketable Securities€48.73M
Total Debt€130.53M
Net Cash€81.81M
Net Cash Per Share€6.73
Tangible Book Value Per Share€10.58
Margins
Gross margin is 29.65%, with operating margin of 10.94%, and net profit margin of 6.22%.
Gross Margin29.65%
Operating Margin10.94%
Pretax Margin8.54%
Net Profit Margin6.22%
EBITDA Margin18.38%
EBIT Margin10.83%
Analyst Forecast
The average price target for STRATEC Biomedical is €36.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€36.00
Price Target Upside34.33% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast-1.64%
EPS Growth Forecast22.60%